Palvella Therapeutics, Inc. Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLA

Rank in Stocks #5633
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company... Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Share Price
$142.85
Last synced: 2026-11-20
Market Cap
$2.08B
Change (1 day)
-2.00%
Change (1 year)
51.82%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Palvella Therapeutics, Inc. (PVLA)

Category

Healthcare
EPS for Palvella Therapeutics, Inc. (PVLA)
EPS as of September 2026 TTM: $-5.50
According to Palvella Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-5.50. At the end of 2025 the company had an EPS of $-3.71, an increase over its 2024 EPS of $-7.83.
EPS history for Palvella Therapeutics, Inc. from 2021 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-5.50 48.25%
2025 $-3.71 -52.62%
2024 $-7.83 -153.12%
2023 $14.74 -149.78%
2022 $-29.61 -47.77%
2021 $-56.69 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$15.66 -384.73%
US
$-7.07 28.55%
US
$-5.29 -3.82%
AU
$12.73 -331.49%
BE
$21.56 -492.00%
NL

Questions about Palvella Therapeutics, Inc.'s earnings per share (EPS)

What is Palvella Therapeutics, Inc.'s earnings per share (EPS)?

Palvella Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-5.50, as of Sep 2026.

What was Palvella Therapeutics, Inc.'s earnings per share (EPS) in 2025?

In 2025, Palvella Therapeutics, Inc.'s earnings per share (EPS) was $-3.71, compared with $-7.83 in 2024.

How has Palvella Therapeutics, Inc.'s earnings per share (EPS) changed since 2021?

From 2021 to 2025, Palvella Therapeutics, Inc.'s earnings per share (EPS) was highest in 2023 ($14.74) and lowest in 2021 ($-56.69).

How does Palvella Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?

Palvella Therapeutics, Inc.'s earnings per share (EPS) ($-5.50) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.